183 related articles for article (PubMed ID: 18031247)
1. The pharmacology of endosomal TLR agonists in viral disease.
Averett DR; Fletcher SP; Li W; Webber SE; Appleman JR
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1468-72. PubMed ID: 18031247
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
Kuznik A; Bencina M; Svajger U; Jeras M; Rozman B; Jerala R
J Immunol; 2011 Apr; 186(8):4794-804. PubMed ID: 21398612
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
Krieg AM; Vollmer J
Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptors: emerging concepts in kidney disease.
Anders HJ; Schlöndorff D
Curr Opin Nephrol Hypertens; 2007 May; 16(3):177-83. PubMed ID: 17420659
[TBL] [Abstract][Full Text] [Related]
5. Antiviral applications of Toll-like receptor agonists.
Horscroft NJ; Pryde DC; Bright H
J Antimicrob Chemother; 2012 Apr; 67(4):789-801. PubMed ID: 22258929
[TBL] [Abstract][Full Text] [Related]
6. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
Makkouk A; Abdelnoor AM
Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.
Zhang X; Kraft A; Broering R; Schlaak JF; Dittmer U; Lu M
Expert Opin Drug Discov; 2012 Jul; 7(7):597-611. PubMed ID: 22607384
[TBL] [Abstract][Full Text] [Related]
8. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
9. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
10. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
Thomas A; Laxton C; Rodman J; Myangar N; Horscroft N; Parkinson T
Antimicrob Agents Chemother; 2007 Aug; 51(8):2969-78. PubMed ID: 17548497
[TBL] [Abstract][Full Text] [Related]
11. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I.
Miyazaki M; Kanto T; Inoue M; Itose I; Miyatake H; Sakakibara M; Yakushijin T; Kakita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Med Virol; 2008 Jun; 80(6):980-8. PubMed ID: 18428149
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
Kanzler H; Barrat FJ; Hessel EM; Coffman RL
Nat Med; 2007 May; 13(5):552-9. PubMed ID: 17479101
[TBL] [Abstract][Full Text] [Related]
13. Presymptomatic differences in Toll-like receptor function in infants who have allergy.
Prescott SL; Noakes P; Chow BW; Breckler L; Thornton CA; Hollams EM; Ali M; van den Biggelaar AH; Tulic MK
J Allergy Clin Immunol; 2008 Aug; 122(2):391-9, 399.e1-5. PubMed ID: 18571707
[TBL] [Abstract][Full Text] [Related]
14. Differential induction of MyD88- and TRIF-dependent pathways in equine monocytes by Toll-like receptor agonists.
Figueiredo MD; Vandenplas ML; Hurley DJ; Moore JN
Vet Immunol Immunopathol; 2009 Jan; 127(1-2):125-34. PubMed ID: 19019456
[TBL] [Abstract][Full Text] [Related]
15. Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis.
Boivin N; Sergerie Y; Rivest S; Boivin G
J Infect Dis; 2008 Sep; 198(5):664-72. PubMed ID: 18662130
[TBL] [Abstract][Full Text] [Related]
16. New developments in Toll-like receptor targeted therapeutics.
Connolly DJ; O'Neill LA
Curr Opin Pharmacol; 2012 Aug; 12(4):510-8. PubMed ID: 22748800
[TBL] [Abstract][Full Text] [Related]
17. Cell Surface Expression of Endosomal Toll-Like Receptors-A Necessity or a Superfluous Duplication?
Mielcarska MB; Bossowska-Nowicka M; Toka FN
Front Immunol; 2020; 11():620972. PubMed ID: 33597952
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory role of toll-like receptors agonists in Plasmodium yoelii liver stage development.
Chen J; Xu W; Zhou T; Ding Y; Duan J; Huang F
Parasite Immunol; 2009 Aug; 31(8):466-73. PubMed ID: 19646211
[TBL] [Abstract][Full Text] [Related]
19. Expression and activity of Toll-like receptors 1-9 in the human term placenta and changes associated with labor at term.
Patni S; Wynen LP; Seager AL; Morgan G; White JO; Thornton CA
Biol Reprod; 2009 Feb; 80(2):243-8. PubMed ID: 18815357
[TBL] [Abstract][Full Text] [Related]
20. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA).
Roelofs MF; Wenink MH; Brentano F; Abdollahi-Roodsaz S; Oppers-Walgreen B; Barrera P; van Riel PL; Joosten LA; Kyburz D; van den Berg WB; Radstake TR
Ann Rheum Dis; 2009 Sep; 68(9):1486-93. PubMed ID: 18765427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
